Shares of Vir Biotechnology fell after the company announced the pricing of its $150 million underwritten public offering.
The stock sank 13% in premarket trading Friday. Through Thursday's close, shares have roughly doubled in value year to date.
The biopharmaceutical company late Thursday said it will sell 15 million shares of its common stock to the public for $10 a share, resulting in gross proceeds of about $150 million before deducting underwriting costs, commissions and offering expenses.
Vir Biotechnology also granted underwriters a 30-day option to purchase up to an additional 2.25 million shares of its common stock at the public offering price, minus underwriting discounts and commissions.
Leerink Partners, Morgan Stanley and Evercore ISI are acting as bookrunning managers for the offering, which is expected to close Monday.
Comments